完整後設資料紀錄
DC 欄位語言
dc.contributor.authorBoobalan, Ramalingamen_US
dc.contributor.authorLiu, Kuang-Kaien_US
dc.contributor.authorChao, Jui-I.en_US
dc.contributor.authorChen, Chinpiaoen_US
dc.date.accessioned2018-08-21T05:53:56Z-
dc.date.available2018-08-21T05:53:56Z-
dc.date.issued2017-04-15en_US
dc.identifier.issn0960-894Xen_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.bmcl.2017.02.059en_US
dc.identifier.urihttp://hdl.handle.net/11536/145364-
dc.description.abstractA series of erlotinib analogues that have structural modification at 6,7-alkoxyl positions is efficiently synthesized. The in vitro anti-tumor activity of synthesized compounds is studied in two non-small cell lung cancer (NSCLC) cell lines (A549 and H1975). Among the synthesized compounds, the iodo compound 6 (ETN-6) exhibits higher anti-cancer activity compared to erlotinib. An efficient method is developed for the conjugation of erlotinib analogue-4, alcohol compound, with protein, bovine serum albumin (BSA), via succinic acid linker. The in vitro anti-tumor activity of the protein attached erlotinib analogue, 8 (ETN-4-Suc-BSA), showed stronger inhibitory activity in both A549 and H1975 NSCLC cell lines. (C) 2017 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectAnti-canceren_US
dc.subjectBSAen_US
dc.subjectErlotiniben_US
dc.subjectEGFRen_US
dc.subjectNSCLCen_US
dc.titleSynthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogueen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bmcl.2017.02.059en_US
dc.identifier.journalBIOORGANIC & MEDICINAL CHEMISTRY LETTERSen_US
dc.citation.volume27en_US
dc.citation.spage1784en_US
dc.citation.epage1788en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000399262600028en_US
顯示於類別:期刊論文